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Abstract
In recent years, science has made great strides in its understanding of the microbiome, discovering that it plays a role in
regulating many body processes. One area of study is the microbiomes interaction and influence on host metabolic processes. Studies using both mice and humans have established a clear correlation between obesity and the composition of
the microbiome, identifying a microbiome unique to obese individuals. Furthermore, experiments with germ-free mice
have shown that the microbiome effects host metabolism, causing germ free mice to increase in mass when inoculated
with normal microbiota. Inoculation with microbiota from obese mice yielded greater increases in mass, showing the
obesogenic effect of the microbiota. The mechanisms through which the microbiome can contribute to obesity are enhanced extraction of energy from food, and increased capacity for nutrient uptake in the gut, and alteration of metabolic
pathways by suppressing fasting induced adipose factor and decreasing AMPK activity. Many of these pathways show
increased activity in obese mice. The enhanced energy extraction coupled with greater deposition of fat mediated by
altered metabolic pathways can contribute to obesity.
The role of the microbiota in obesity, combined with decades-old observations that antibiotics, particularly early in life,
increased the weight of livestock, led to a hypothesis that antibiotics can disrupt the development of the microbiome,
causing metabolic changes, leading to obesity. Recently, this hypothesis has been tested, both in studies utilizing mice, and
in many epidemiological studies. This paper will evaluate the available evidence to determine if exposure to antibiotics
early in life can lead to increased incidence of obesity later.
Introduction
In 1671 when Antony van Leeuwenhoek first spied “animalcules,” now known to us as single cell organisms, through his
homemade microscope, he set into motion a centuries long
scientific endeavor to discover, describe, catalogue and gain
a deeper understanding of the vast microbial world that surrounds us. This laid the groundwork for the development of
the germ theory by Louis Pasteur and Robert Koch over the
course of the 1860’s and 1870’s. Germ Theory, the theory that
many diseases are caused by microbial agents, revolutionized
medicine leading to many advances such as the disinfecting
of wounds, the appreciation of the need for a sterile environment during surgery, and in 1921 the fortuitous discovery
of penicillin by Alexander Fleming. Germ theory also had a
profound influence on the attitudes of medicine and society
at large towards “germs.” Although only a tiny fraction of
microbes are pathogenic, they became indelibly associated,
both in the popular imagination and in medical practice, with
sickness and disease. This focus on microbe pathogenicity has
yielded tremendous benefits to public health, in fact antibiotics
were among the primary drivers of rising life expectancy in
developed countries in the mid twentieth century (Armstrong,
1999), but antibiotics, for all their benefits, came with costs as
well, namely their effect on the native flora.
Discovery of the body’s native flora began in the mid 1880’s
when an Austrian pediatrician, Theodore Escherich, observed
the eponymously named Escherichia coli in the stool of healthy
children. Discovery continued apace and the realization set in
that there was a large, diverse, community of microbes that
colonized the skin, nasal and oral cavities, and the urogenital
and gastrointestinal tracts of healthy people, making up their
native flora. As early as the 1970’s there was already an idea

of the number of microbes, then estimated to number roughly 1014, living primarily in the gastrointestinal tract, and some
idea of ecology of this diverse community (Savage, 1977). Until
relatively recently, it was assumed that the microbes living in
the colon lived a largely commensal existence, dining on food
indigestible to the human host but not interacting with the
host in any meaningful way. With this understanding collateral
damage to the gut bacteria because of antibiotics was no great
concern, with the worst-case scenario being an unwanted
bloom of C. Difficile. However, in recent years and particularly
since the launch of the Human Microbiome Project, an entirely
different picture has emerged, one that includes many symbiotic relationships between the native flora and the host, in
fact so enmeshed is the host-symbiont relationship, that they
have been described as one “supraorganism (Turnbaugh, et al.,
2007). This new understanding demands a closer look at the
possible effects of antibiotics on our microbiome.
This paper will explore the possible link between antibiotics
and obesity. First it will lay the groundwork with a thorough
exploration of the literature linking the state of the microbiome to obesity as well as an understanding of the underlying mechanisms. Then it will consider the evidence that a
disturbance of the microbiota through antibiotic treatment
can cause obesity along with proposed causative mechanism.
Finally, it will propose ways to mitigate the effects of the antibiotic treatment.

Methods
Information for this paper was obtained primarily through online searches utilizing google scholar as well as well as numerous
databases accessed through Touro college’s library system.
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Definition of “Core Microbiome”
The first step to determining if obesity is associated with an
altered microbiome is establishing the baseline values defining
what a “normal” gut microbiome looks like. This task is complicated by the wide diversity of gut microbial populations found
across different geographical areas and cultures, and even within
communities and cultures. In fact, in one study “there was not
a single abundant (deﬁned as >0.5% of the community) bacterial species shared by all 154 individuals” involved in the study
(Turnbaugh P. J., 2009) . However, if one looks at the microbiome
on the level of phyla, a strong pattern begins to emerge, with
bacteria from the phyla Firmicutes and Bacteriodetes representing, in one study, 92.6% of the microbiota (Ley, et al., 2006).
These 2 phyla and their respective ratios can serve as one definition of a core microbiota.
Another way of defining the core microbiome is, rather than
focusing on the species or phyla present, focusing on the various genes present. Various studies utilizing this methodology
have found that regardless of the vast diversity of the microbial
makeup of the gut flora, there exists a “wide array of shared microbial genes, comprising an extensive, identifiable ‘core microbiome’ at the gene, rather than at the organismal lineage, level”
(Turnbough, et al., 2009). While both definitions are useful, this
paper will primarily utilize the second definition of the microbiome as a set of genes rather than ratio of different bacterial
phyla. The reason for this is that a focus on genes can better
illuminate any products of the microbiome that may affect host
metabolic pathways, possibly contributing to obesity.

Association of Obesity with Altered Microbiome
Having established a baseline microbiome, we can now explore
any obesity associated changes that may occur. First, we will explore the changes in the ratio of Firmicutes and Bacteroidetes
associated with obesity.
In one experiment, mice heterozygous for obesity ob/+ (due to
a defective leptin gene) were mated producing litters consisting
of a mix of obese (ob/ob) and lean (ob/+ and +/+) phenotypes.
Microbial ecology in the gut, specifically the ratio of Firmicutes
to Bacteroidetes, which is typically similar among members of
a family living together, was found to be consistent in the heterozygous mothers as well as the ob/+ and +/+ children. In the
homozygous ob/ob mice of the same litter however, a sharp
increase in abundance of Firmicutes relative to Bacteroidetes
was observed (Ley, et al., 2005). This shows a clear correlation
between obesity and the composition of the gut microbiome.
In another experiment, 12 obese individuals were randomly
placed on either a fat or carbohydrate restricted diet and their
gut microbiota was monitored over the course of a year for any

88

discernible shift in the microbiota as they lost weight. Initially,
obese people had more firmicutes and fewer Bateroidetes than
lean controls. However, over the course of the year as their
weight dropped, the ratio of Firmicutes to Bacetoidetes began
to more closely resemble a typical lean profile (Ley, et al., 2006).
Together, these two studies, encompassing both mice and men
and showing both an increase in abundance of Firmicutes as an
obese phenotype was acquired in the mouse experiment and
a decrease in its abundance as weight was lost in the human
experiment, firmly establish that obesity is associated with an
altered microbiome.

Can the Gut Microbiome Cause Obesity?
Having established a strong correlation between obesity and altered gut microbial ecology, we can now explore the possibility
that the microbiome can be a causative agent in obesity.
There seems to be good experimental evidence, at least with
mice, that this is the case.
In one experiment, mice were divided into three groups. One
group was raised “Germ Free” meaning that their gut was sterile. Another group consisted of regular, conventionally raised
mice, and acted as a control. A third group was initially raised
germ, free but subsequently inoculated with gut bacteria at 7-10
weeks by spreading a suspension of cecal content from the control group mice on their fur. Comparison of germ free and regular mice at 8 to 10 weeks found that regular mice had 42% more
body fat than their germ-free companions and had epidydimal
fat pads weighing 47% more, all while eating 29% less food. After
a 14-day colonization, a process known as conventionalization,
the third group of mice experienced a dramatic 57% increase in
total body fat and a 61% increase in epididymal fat pad weight
all while their chow consumption decreased to that of the normal mice (Backed, et al., 2004). This experiment shows that gut
microbiota has a powerful effect on metabolism and fat storage.
The initial low-fat state of the germ-free mice even with their
above average food intake and their dramatic increase in fat,
even in the face of decreased chow consumption, as they were
conventionalized, indicates that a normal microbiome plays a
key role in regulating fat in mice.
Having established the effects of a normal microbiome, let us examine the effects of an obese one.Toward this end, an experiment
was constructed in which germ-free mice were colonized by gavage (meaning they were fed by tube) with the cecal contents of
either wild type +/+ or genetically obese ob/ob (leptin deficient)
mice. In the 14-day period following the colonization food consumption in the (ob/ob) and (+/+) transplanted groups was not
statistically different (55.4±2.5g for ob/ob against 54.0±1.2g for
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+/+) and they both ate the same type of chow (no difference in
caloric density). Despite this, the mice colonized with ob/ob microbiota exhibited a significantly greater increase in body fat than
those colonized with +/+ microbiota with the ob/ob colonized
mice increasing body fat by 47±8.3% and the +/+ colonized mice
increasing by just 27±3.6% (Turnbaugh,et al., 2006).
The dramatic difference in body fat between the two groups
strongly indicates that the obese microbiome causes greater
adiposity, and gives rise to the possibility that the microbiome
can play a role in its development.

Mechanisms of Microbiome Influence on Adiposity
The classic, somewhat simplistic understanding of the development of obesity is to take the calories of the food eaten,
subtract calories burned by both the basal metabolic rate and
any additional energy expenditures for various activities, and
assume that the remainder is stored as fat in adipose tissue
throughout the body. Our exploration of the mechanisms
through which the gut microbiota increase adiposity will illuminate several ways that this seemingly straightforward and
commonsense equation can be altered.
One mechanism proposed is that all microbiomes increase the
bodies capacity for energy harvest from food eaten by excreting exoenzymes that break down polysaccharides that the host
is unable to metabolize. Once degraded into monosaccharides
and short chain fatty acids, both the bacteria and the host
readily take up the product, accruing extra calories to the host
from the same food. It is further hypothesized that the changed
obese microbiome performs these tasks more efficiently extracting even more calories from the same unit of food with the
host reaping some of the benefits. This hypothesis is buttressed
by numerous lines of evidence.
The first of these is a simple comparison of the energy remaining in the feces of regular mice as opposed to genetically
obese mice. Bomb calorimetry showed that ob/ob mice have
significantly less energy remaining than regular mice, yielding 3.2
kcal/g compared to 3.4 in regular mice (Turnbaugh, et al., 2006).
This is simple, clear, empirical evidence that an obese microbiome harvests more energy than a standard, lean microbiome.
Another line of evidence involves a genetic analysis of the microbiome, specifically of genes encoding enzymes that catalyze
the breakdown of polysaccharides indigestible to their hosts.
In one study, a sequencing of 18 Human microbiomes identified
genes for 156 carbohydrate- active enzymes, which are enzyme
families that break down carbohydrates, including 77 glycoside
hydrolase, 21 carbohydrate-binding module, 35 glycosyltransferase, 12 polysaccharide lyase and 11 carbohydrate-esterase

families. These genes consisted of fully 2.62±.013% of all the
microbial genes sequenced, a higher percentage than any other
identified group of genes. Furthermore, an analysis of lean and
obese twins found that the obese twins had a microbiome that
was significantly enriched in genes coding for carbohydrate,
lipid, and amino acid metabolism as compared to that of their
lean twins (Turnbough, et al., 2009).
Mice studies have yielded similar results, with ob/ob mice
having microbiomes containing more genes coding for various
carbohydrate-active enzymes as compared with their lean littermates. A predicted result of this would be an increased concentration of the products of bacterial fermentation of these
polysaccharides, such as butyrate and acetate, in the cecum
of the ob/ob mice. This prediction was borne out, with cecal
butyrate concentration of obese mice double those of lean
mice and acetate levels 20% higher (Turnbaugh, et al., 2006).
Interestingly this same study also found a greater abundance
of archaea in the obese mice than their lean counterparts.
Archaea oxidize the hydrogen produced as a by-product
of fermentation by gut bacteria, turning it into methane. By
removing a product of the fermentation reaction, they increase its efficiency, serving to further enhance energy extraction by the obese microbiome. Indeed, in a study of mice
colonized with archaea commonly found in the human gut,
Methanobrevibactor smithii and B. thetaiotamicron, a significant increase in the efficiency of bacterial polysaccharide fermentation leading to an increase in adiposity in the mice was
observed (Samuel & Gordon, 2006)
In addition to increasing energy extraction from food, there is
also evidence that the microbiome increases the hosts capacity
for uptake of nutrients in the gut. In one experiment, germ-free
and conventionalized mice were fed a glucose solution. After fifteen minutes, the level of glucose uptake was found to be twice
as high in the conventionalized mice as in the germ-free ones
(Backed, et al., 2004). Additionally, the microbiome is essential to
the development of the capillary network to transfer these nutrients from the intestines to the hepatic portal vein. Germ-free
mice were found to have arrested development of this capillary
network, and upon conventionalization, developed it to normal
levels within ten days (Stappenbeck & Hooper, 2002).
These lines of evidence collectively paint a picture of a microbiome that extracts more energy from food by breaking down
complex polysaccharides that the host is unable to metabolize
on his own and amplifying the hosts ability to absorb the resultant monosaccharides, providing one possible mechanism for
the microbiome to contribute to obesity.
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Another mechanism proposed is that the microbiome modifies
cell signaling pathways to increase fat storage, that is, to direct
more of the energy harvested toward adipocyte storage rather than other metabolic functions. Two metabolic pathways are
involved, one of which involves fasting-induced adipose factor
(Fiaf) which is a lipoprotein lipase inhibitor (Backed, et al., 2004).
Lipoprotein lipase facilitates deposition of fat in adipocytes. Fiaf,
which inhibits it, is a crucial regulator of this process. Fiaf is produced by brown and white fat, the liver, and the intestine. The
microbiome suppresses the production of Fiaf in the intestinal
epithelium, thereby increasing the activity of lipoprotein lipases,
resulting in more triglycerides being incorporated into adipocytes.
Experimental evidence for this machanism comes from a study
that compared regular germ-free mice, germ-free mice incapable of producing Fiaf (Fiaf-/-), and conventionalized mice both
with and without the Fiaf gene. The regular germ free mice,
as expected were the leanest. Germ free Fiaf-/- mice however, were found to have nearly the same amount of fat as their
conventionalised wild type peers. Furthermore, a conventionalization of the germ free Fiaf knockout mice yielded a minimal
increase in body fat of 10±8% versus 55±16% for the wild type
germ free mice. Conventionalization of heterozygotes (Fiaf +/-)
yielded an intermediate result, consistant with the hypothesis.
Additionally comparison of mRNA of conventionalised and
germ free wild type mice revealed camparitively less Fiaf expression in the small intestines of the the former, expression
elswhere though was unaffected (Backed, et al., 2004). Other
studies have had similar findings, including one that found that
while regular germ free mice were resistant to obesity induced
by consuming an “american diet” in their case chow with higher
fat content and more easily digested sugars, Fiaf -/- mice had
lost this resistance (Backhed, et al., 2007). These findings point
to fasting induced adipose factor as a major component of the
microbiomes contribution to adiposity.
Another pathway involves levels of AMP-activated protein kinase, or AMPK (Backhed, et al,. 2007). AMPK is a key enzyme
regulating metabolism, serving as the lynchpin of a complex web
of metabolic pathways maintaining proper ATP levels. AMPK
ramps up energy production in response to metabolic stresses.
It is triggered primarily, as its name indicates, by an increased
ratio of AMP to ATP, but also by numerous other factors such as
an elevated ratio of NAD to NADH, and the hormones leptin
and adiponectin (Kahn, et al,. 2005) .The microbiome is thought
to decrease AMPK activity, leading to lower energy expenditure,
with more calories remaining to be deposited as fat.
Evidence for this mechanism is based on a number of observations. The first is that germ free mice were found, using an
immunoblot assay, to have phospho-AMPK, which is the active
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form, at concentrations 40% percent greater than their regular
peers in their gastrocnemeus muscles. Consistant with these
findings AMP levels in the germ-free mice were foud to be 50%
higher. Additionally, many other enzymes involved in the fatty
acid oxidation pathway triggered by AMPK showed fluctuations
consistant with increased fatty acid oxidation. In this pathway,
AcetylCoA carboxylase converts Acetyl CoA to Malonyl CoA,
Malonyl CoA inhibits carnitine-palmitoyl transferase-1 (Cpt1),
which catalyzes the rate-limiting step for uptake of long chain
fatty acids by mitochondria, AMPK phosphorylates AcetylCoA
carboxylase, inhibiting it and thereby increasing fatty acid
oxidation (Kahn, et al, 2005). A 43% increase in the levels of
phosphorylated AcetylCoA carboxylase was found using an
immunoblot assay and a 17% increase in the level of Cpt1 was
found with a biochemichal assay, in germ free over that of regular mice,both consistant with increased fatty acid oxidation
(Backhed, et al,. 2007).
Collectively, these lines of evidence paint a picture of a microbiome that acts on both sides of the energy equation, harvesting
more energy from food through greater polysaccharidase activity, conserving more of that energy through, and depositing a
greater portion of it as fat.

Can Antibiotics Contribute to Obesity?
Having gained some appreciation of the influence of our microbiota on our metabolism and its role in promoting adiposity,
we can now explore the role of antibiotics on this complex
system. Specifically, we will explore whether the disruption to
the microbiota caused by antibiotics, particularly early in life, can
affect the body mass of the host later in life by either promoting
or inhibiting weight gain.
There is extensive evidence that antibiotics promote weight
gain, from veterinary medicine, animal models, and epidemiological studies.
In the 1950’s Veterinary scientists showed that giving pigs (Taylor
& Gordon, 1955) and other livestock (Jukes & Williams, 1953)
sub-therapeutic doses of antibiotics increased their growth
causing them to gain more weight without increasing feed
consumption. It subsequently became common practice among
farmers to mix low doses of antibiotics into the feed of pigs,
cows, sheep, and poultry, increasing their weight, a practice that
continues to this day. The effect on weight gain is significant, a
meta-analysis of numerous studies gauging the weight boosting
effects of adding antibiotics to feed in pigs found an increase in
weight gain of up to 15% and an increase in feed efficiency (an
industry term for amount of meat produced per unit of feed) of
up to 6%.The strongest effects were found when the antibiotics
were given from birth with lesser, though still significant effects
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found if they were given at later dates (Hays, 1969). Evidence
that the weight gain is connected to disruption of the microbiota comes from experiments with germ free chickens. Germ free
chickens given feed containing antibiotics that had a growth promoting effect on regular chickens showed no similar increase in
growth from the treatment (Coates, 1963), indicating that the
weight gain is a result of modulation of the microbiome. These
veterinary studies on regular and germ free animals, combined
with the everyday experience of farmers for the last 70 years
provide one line of evidence that antibiotic use has a role in
weight gain. Importantly, as the data showed, the effect is greatly
magnified in early life, suggesting that the early microbiome may
be particularly vulnerable to whatever disruption causes the
weight gain, a theme that will be expanded on shortly.
More evidence comes from experiments with model organisms,
namely Mus Musculus, the mouse. Additionally, these experiments shed light on the magnified effects of antibiotics found
in early life.
In one experiment the effects of sub-therapeutic antibiotic
treatment (STAT) was tested on mice to attempt to replicate its
observed effect on farm animals and gain some insight into its
mechanisms. In the experiment mice were exposed, starting at
weaning, to various common antibiotics by putting them in their
drinking water at sub-therapeutic levels, and were compared
to a control group using various metrics. After a seven-week
exposure, the STAT mice were found to have greater fat mass
than the control group as well as a significantly higher percent
body fat. Curiously although fat mass was greater in the STAT
mice, total mass was not significantly greater at seven weeks,
though later measurements taken from 8 to 26 weeks did show
increased mass in the STAT mice (Cho, et al., 2012).
Utilization of other metrics allows for a deeper understanding
of the processes driving the adiposity of the STAT mice. One
important measure taken was the level of Gastric Inhibitory
Polypeptide (GIP). GIP, a hormone secreted by K cells in the
small intestine, stimulates lipoprotein lipase activity, increasing
fat storage and contributing to adiposity (Miyawaki, et al., 2002).
GIP levels were found to be substantially elevated in STAT mice
(39.1±2.5 pg/ml) compared to the controls (24.4±4.2 pg/ml).
This provides a possible mechanism for the observed increase
in adiposity.
Microarray analysis of differential gene expression in hepatic tissue yielded deeper insights into the metabolic changes wrought
by STAT. Comparison of STAT and control mice found upregulation of pathways for lipogenesis and triglyceride synthesis in the
STAT mice, further contributing to adiposity.

Examination of the gut bacteria in the STAT mice yielded further insight. Although the overall number of bacteria did not
change significantly, the composition of the microbiome did
change, with the abundance of Firmicutes increasing relative to
that of Bacteroidetes, which, as discussed earlier, is typical of
obese microbiomes. Additionally, examination of the cecal contents of the STAT mice found higher levels of butyrate and acetate, suggesting increased energy capture through fermentation
of complex carbohydrates indigestible to the mice, as discussed
earlier. Supporting evidence came from metabolic cage experiments showing no difference in caloric intake but a lower caloric output in fecal pellets in STAT mice compared to controls
(Cho, et al., 2012).
Taken together, these measurements paint a picture of antibiotics changing the composition of the microbiome, leading to
metabolic changes causing adiposity and weight gain, and suggest
that perhaps antibiotics can contribute to obesity in humans as
well.

Increased Effect in Early Life
Greater weight gain was observed in farm animals when STAT
was started earlier in life. Mouse studies have explored the importance of the timing of antibiotic exposure further, experimentally confirming these observations and expanding upon
them. They found that early life is a critical time in metabolic
development and exposure to antibiotics at this sensitive stage
can permanently alter host metabolism.
Evidence for these claims comes from an experiment comparing
mice started on low dose penicillin (LDP) at weaning (LDP-w) to
mice where LPD was started shortly before birth(LDP-b) so that
the initial colonization with maternal microbiota would be altered.
A control group was maintained that was not exposed at all.
The experiment found that earlier administration of antibiotics
did have amplified effects.The growth rate for LDP-b was greater than the control, the fat mass as well as the total mass of
adult LDP-b male mice was greater than that of LDP-w mice and
the control (Cox, et al., 2014), demonstrating enhanced effects
of earlier antibiotic administration. Sexual dimorphism was apparent in the results with the females experiencing lesser if any
effects, a finding that remains unexplained. Metabolic differences
between the LDP-b and LDP-w mice were found as well with
the LDP-b mice having greater expression of genes involved in
adipogenesis than LDP-w mice.
The mammalian early microbiome is a dynamic, changing environment typically showing a pattern of succession as different taxa first dominate then diminish (Pantoja-Feliciano, et al.,
2013). Altered representation of some of these taxa has been
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associated with obesity (Kalliomaki, et al,. 2008). Typically,
Lactobacillus is prominent in nursing animals, as was indeed the
case with the controls. The LDP-b mice however, showed much
lower levels of Lactobacillus, as well as other groups whose population typically peak in early life such as Candidatus Arthomitus
and Allobaculum (Cox, et al., 2014). Although the precise roles
of these microbes are not known, their suppression by LDP and
the dramatic phenotypic effects that follow suggest some role
in metabolic development.
In an experiment with worrying implications for human obesity,
some LDP mice were switched to high fat diet at 17 weeks, and
were compared to control groups with just a high fat diet or
just LDP. The growth promoting effects of LDP were accentuated by the high fat diet producing fat and weight gain surpassing
that produced by the high fat diet or LDP alone.
More worrying still, the metabolic effects of LDP lasted into
adulthood even after treatment finished. Mice that received LDP
for only four weeks after birth still experienced greater fat and
total mass accumulation from 6-20 weeks. This weight gain persisted even though the microbiota had appeared to normalize.
Finally, to demonstrate that the metabolic and phenotypic
changes observed were a result of an altered microbiota
and not some direct effect of the penicillin, cecal microbiota
were transferred from 18-week-old control and LDP mice to
3 week germ-free mice. The mice inoculated with the LDP
microbiota increased total mass and fat mass at a faster rate
(.078 g/day total mass and .058 g/day fat mass faster) than
those inoculated with the normal microbiota (Cox, et al.,
2014).
These studies provide convincing evidence, as much as can be
inferred from model organisms, that antibiotics contribute to
obesity through disruption of the microbiota, and that early life
is a particularly sensitive time when disruption of the developing
microbiome can have long lasting metabolic effects.

Epidemiological Studies
The findings in model organisms that antibiotic exposure, particularly in early life, can lead to obesity, have important implications for human health. However, results in model organisms
do not always translate into results in humans. Since ethical
concerns preclude the types of randomized, controlled studies
routinely performed with model organisms from being done on
humans, we must rely on epidemiological evidence. Fortunately,
there are a wealth of well-constructed epidemiological studies
demonstrating that antibiotic exposure in infancy is correlated
with obesity later in life.
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In a study involving 28354 mother baby pairs from the Danish
National Birth Cohort, antibiotic exposure in the first six
months of life was correlated (with an odds ratio of 1.54,
well above the threshold for showing correlation) with an increased risk of being overweight at 7 years (Ajslev, et al., 2011).
Supporting these findings are results from a study utilizing
11532 children from the Avon Longitudinal Study of Parent and
Children. This study examined antibiotic exposure during three
early-life time windows, 6< months, 6-14 months, and 15-23
months. Exposure under six months was, once again, strongly
correlated (p<.001) with increased body mass at 10, 20, and
38 months. However, exposure from 6-14 months showed no
effect and exposure at 15-24 showed a modest weight gain at 7
years (Trasande, et al., 2013). A Canadian study combining data
from health records and a Canadian longitudinal birth cohort
study further bolstered these findings. The study found that
children who received antibiotic treatment in the first year of
life were more likely to be overweight at ages 9 and 12 than
their untreated peers (32.4% overweight if exposed vs. 18.2%
if not). Additionally, researchers noted a greater prevalence of
elevated central adiposity, a precursor of metabolic syndrome,
among the treated children (Azad, et al, 2014). A longitudinal
study in the USA (Bailey, et al., 2014)and a global cross sectional
study (Murphy, et al., 2013) found similar results as well. Several
the studies (Trasande, et al., 2013) (Murphy, et al., 2013) found a
strong sexual dimorphism, with the effect much greater in boys,
and nearly all the studies showed some difference between girls
and boys, with the boys seeing greater weight gain than the
girls, a finding that while replicated many times in both model
organisms and in humans, has not been satisfactorily explained.
The collective weight of these epidemiological studies gives
great credence to claims that antibiotics contribute to obesity.

Mitigating the Effects of Antibiotics
Even with all the evidence of detrimental side effect of antibiotics, stopping their use is obviously not an option. Antibiotics
are a cornerstone of modern medicine, without which life expectancy would surely drop precipitously. However perhaps a
bit of restraint in prescribing antibiotics to children is in order.
Rates of antibiotic prescriptions in the USA are unnecessarily
high, with some analyses finding that fully half of all antibiotic
prescriptions written are unnecessary (Nyquist, et al., 1998).
Although antibiotic prescription rates among children and adolescents have dropped since that finding (Lee, et al., 2014), prescription rates in the USA are still high compared to some other
countries. In Sweden, for example, antibiotic use is 53% lower
than in the USA (Ternhag & Hellman, 2010). This indicates that
prescription levels can still be lowered significantly without adversely effecting public health. While some antibiotic exposure
may be unavoidable for many children, even merely reducing the
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number of rounds of antibiotics they take reduces their chance
of developing obesity later in life (Bailey, et al., 2014).
One final action possible to mitigate the obesogenic effects of
antibiotics on children is to prescribe narrow spectrum antibiotics when possible. One study, despite finding significant
correlation between broad-spectrum antibiotics in the first two
years of life, found no such correlation for narrow-spectrum
antibiotics (Bailey, et al., 2014).

Conclusions

I., Blaser, M. (2014). Altering the Intestinal Microbiota during
a Critical Developmental Window Has Lasting Metabolic
Consequences. Cell, 705-721.
Hays,V. (1969). The Use of Drugs in Animal Feeds. National
Academy of Sciences, 11-30.
Jukes, T., & Williams, W. (1953). Nutritional Effects of Antibiotics.
Pharmacology Review, 381-420.
Kahn, B. B., Alquier, T., Carling, D., & Hardie, D. (2005). AMPactivated protein kinase: ancient energy gauge provides clues
to modern understanding of metabolism. Cell Metabolism,
15-25.

In conclusion, the evidence for an obesogenic effect of early-life
exposure to antibiotics is substantial and convincing. The many
mouse studies demonstrating the influence of the microbiome
on metabolism and its role in obesity give ample reason to suspect that perturbations of the microbiome with antibiotics may
have some effect on obesity. The evidence from farm animals,
mice, and epidemiological studies serve to confirm that suspicion, showing that antibiotic exposure in infancy contributes to
one’s chances of developing obesity later in life.

Kalliomaki, M., Collado, M., Salminen, S., & Isolauri, E. (2008).
Early differences in fecal microbiota composition in children
may predict overweight. American Journal Clinical Nutrition,
534-538.
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